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Abstract: The process of antibody-dependent cell-mediated cytotoxicity (ADCC) makes use of the innate 
immune cells providing antitumor cytotoxicity activated by antibodies linked to target cells. Natural killer 
(NK) cells are a small set of lymphocytes, but are considered the most important cells among those able to 
induce ADCC. They provoke innate immune responses and harmonise spontaneous cytotoxicity towards 
tumor and virus-infected cells. They are able to swiftly produce biochemical signals and cytokines so as to 
stimulate subsequent adaptive immune responses. Immunotherapeutics that target NK cells, augmenting 
their immune response, can cause the antitumor dynamics of the antibodies to be improved. The recent 
developments in the field of NK cell immunotherapy and genotypic factors which might affect patient 
responses to antibody-dependent immunotherapies are the main subject of this review, with a particular focus 
on the manipulations and strategies used to augment ADCC. In the next years combined treatment with 
monoclonal antibodies (mAbs) and immunomodulatory drugs will be an important part in antitumor therapy. 
The main challenge remains the difficulty in distinguishing in the clinical setting, between the target effect 
that many mAbs exert against specific cell membrane receptors and the ADCC effect that they too also can 
induce. Drugs able to activate NK cells, that are major actors in mAb-mediated ADCC, will improve the 
ADCC effect against tumors.
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Introduction
Cell-mediated immune defence includes the antibody-
dependent cell-mediated cytotoxicity (ADCC), where an 
immune system effector cell actively lyses a target cell after 
its binding, by specific antibodies, to the membrane-surface 
antigens.
ADCC requires three different players working 
together: the cell expressing target antigens, the antibody 
and the immune effector cells expressing Fc-gamma 
receptors (FcγR). 
In cancer therapy, the target on the cell surface may 
be an antigen highly expressed by many tumors such as 
epidermal growth factor receptor (EGFR). The antibody 
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may be a monoclonal antibody (mAb), preferentially of class 
IgG1 or IgG3 since these two antibodies link any kind of 
FcγR. The third actor is the effector cell, harbouring the 
FcγR. There are many different FcγRs (Ia, IIa-b-c, IIIa-b), 
including one (FcγR IIb) with a strong inhibitory effect. All 
the effector cell lineages but one harbour both activating 
and inhibitory FcγR. Noteworthy is the finding that the 
affinity of FcγR IIb to IgG1 is higher than the affinity of 
IgG1 with the activating receptors. 
Unlike other effector cells, natural killer (NK) cells 
harbour only activating FcγRs (FcγR IIIa, also known as 
CD16a, and FcγR IIc, also known as CD32c) and therefore 
these cells are considered the most important effectors of 
ADCC in humans.
Our review will focus on NK cells, mAbs, possible 
mechanisms to enhance ADCC and preclinical and clinical 
data focusing on ADCC in vivo.
NK cells: innate, adaptive, or both?
NK cells are innate immune effector cells that are able to 
recognise and destroy abnormal cells, in particular tumor or 
virus-infected cells. 
Different from antigen-specific T cells, NK cells are 
innate immune lymphocytes. In the germline, NK cells are 
not able to rearrange genes encoding receptors, and, thus, 
they do not recognize many antigens and molecules of the 
major histocompatibility complex (MHC) (1). 
In humans, there are two important lineages of NK cells, 
classifiable according to the expression of CD56: CD56dim 
and CD56bright. CD56dim NK cells are either CD16+ or 
CD16−. They constitute around 90% of the NK cells in 
blood and primarily negotiate cytotoxicity. Conversely, 
CD56bright cells are CD16− or CD16dim and form 5–15% of 
total NK cells. They produce mostly cytokines and play a 
minor role in cytolytic processes (1). 
Elimination, equilibrium and escape are the three phases 
currently proposed in the context of cancer immunoediting, 
which range from surveillance to escape. In the innate 
response, effector cells (i.e., NK cells) and secreted IFN-γ 
are able to initially eliminate transformed cells. This results, 
in the equilibrium phase, in immune sculpting and selection 
of tumour variants, that are less immunogenic and become 
resistant to immune effectors (2).
NK cells are genetically programmed to destroy cellular 
malignancies through unique surface receptors that, upon 
contacting a target cell, transmit either inhibitory or 
activating intracellular signals. Acquisition of the capacity 
to kill comes only after the NK cell is rendered tolerant 
to healthy self cells through interaction with naturally 
expressed MHC I molecules (1,2). In fact, NK cells mainly 
target cells with a low expression of class I MHC (MHC-I), 
or with expressions of MIC-A or MIC-B which represent 
markers of stressed cells (1). The directed exocytosis of 
cytolytic granules, with the subsequent release of granzymes 
and perforins, and the expression of cytotoxic effector 
molecules in response to activation such as Fas ligand, is 
the mechanism by which NK cells perforate the plasma 
membrane of the target cell and cause apoptosis (1). ADCC 
was firstly described as a mechanism of where effector 
cells secrete cytotoxic molecules and lyse antibody-coated 
target cells. However, it is now understood as a multi-tiered 
process involving coordination and crosstalk of immune 
cells. Moreover, in recent literature, NK cell activation 
has been shown to provoke functions akin to those of a 
memory cell (3-6). 
Thus, a reassessment of the role of the NK cell even in 
adaptive immunity is necessitated by these observations, 
taking into account that NK cells do not lead to immunity 
on their own, do not carry antigen specific recognizing 
receptors and do not make memory on their own. They are 
innate cells that are part of the network but do not do the 
specific adaptive job.
The importance of NK cells  in tumor immune 
surveillance was studied primarily in mice lacking NK cells 
that clearly demonstrated an increased susceptibility to 
cancer (7-9). In humans, NK cell deficiencies are tormented 
by acute persistent viral infections, in particular the herpes 
simplex virus (10).
NK cell effector properties can be made use of in 
treating certain tumors due to their ability to evoke ADCC. 
Antibody-dependent tumor killing through NK mediation 
takes place via various routes, including cytotoxic granule 
exocytosis, tumor necrosis factor (TNF) family death 
receptor signalling and the release of a pro-inflammatory 
cytokine, such as interferon-gamma (IFNγ). Target cell 
apoptosis is caused by both the uptake of granzymes and 
perforins by target cells and by TNF family death receptor 
signalling, whereas NK-cell-released IFNγ activate nearby 
immune cells to encourage antigen presentation and 
adaptive immune responses (11).
ADCC
Recent studies have confirmed the role of ADCC in clearing 
tumors and have concentrated on accentuating ADCC in 
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this context.
ADCC depends on the bifunctional structure of IgG 
molecules. The binding of the mAbs via the fragment 
antigen-binding (Fab) portion to the antigen associated 
with the tumor on the target cell confers ADCC specificity. 
When both cell antigen and an activating FcγR are engaged 
respectively by the Fab and Fc portions of the mAb, ADCC 
is initiated, since this creates a bridge from the tumor cell 
to the effector cell. The recognition of target cells is then 
combined to a lytic attack on the target cell mounted by 
effector cells. ADCC does not depend on the immune 
complement system in which targets are also lysed but 
no other cell is required. ADCC requires an effector cell, 
mainly NK cells (due to the lack of inhibitory FcγR IIb) 
that typically interact with IgG antibodies (12) (Figure 1).
Clynes et al. [2000] (13) suggested that Fc is perhaps 
the dominant component in vivo, causing host responses 
to destroy target cells. Those researchers showed that in 
mice lacking FcγR I and FcγR III, there was a significant 
reduction in the anti-tumor effects of certain mAbs. 
Conversely, mice with a deficiency in the inhibitory receptor 
FcγR IIb were seen to have tumor growth inhibition and 
enhanced ADCC (14). 
Several studies have demonstrated that the anti-tumor 
activity of specific mAbs is linked to high affinity FcRs 
genotype (14).
Much effort has been made on the basis of these findings 
to manipulate the Fc region to optimize their therapeutic 
effects, such us glycoengineered mAbs to improve their 
cytotoxicity and neonatal Fc receptors (FcRn) engineered to 
increase the Fc domain affinity and also their half-life (15,16).
Furthermore, recently a novel concept has come to the 
fore. Concurrently to the direct short-term effects of mAbs, 
these are now also regarded as being immunomodulatory 
molecules able to recruit Fc-receptor-expressing innate 
immune cells so as to bring about a long-term endogenous 
adaptive immune response (with an effect like a vaccine), 
which is accountable for tumor development being 
controlled in a better and more sustained way as observed 
in certain patients (16).
Monoclonal Abs functioning through ADCC
Following binding to transformed cells or following 
neutralizing trophic signals delivered by the tumor stroma, 
mAbs targeting tumors provoke antineoplastic effects. As 
a result, there may be various mechanisms determining 
the clinical efficacy of these agents, which are often not 
mutually exclusive (17).
It has recently become clear that mAbs might exert 
action mechanisms different from the selective blockade of 
cell membrane receptors.
Following rituximab (anti-CD20), approved in 1997 for 
the treatment of non-Hodgkin’s lymphoma (18-20), various 
mAbs, including trastuzumab (21), cetuximab (22), the anti-
GD2-mAbs (23) and daratumumab (anti-CD38 mAb) (24) 
have become the standard care in treating both solid and 
hematological malignancies [for an updated list, refer to (25)].
The Fc region may also utilise NK-mediated ADCC as a 
mechanism of action. Thus, NK cells are influential effectors 
in the immune response to tumors driven by mAbs, and data 
highlighting their importance continue to amass (1,8,26).
Despite the fact that various effective antibodies have 
come to the fore, responses that are long-term and durable 
are hard to determine; thus, resistance and relapse continue 
to represent significant limitations in cancer therapy (27). 
In particular, cetuximab, as well as blockading downstream 
EGFR signalling, has several clinically significant immune 
mechanisms: (I) activating the FcγR IIIa on NK cells 
and ADCC; (II) IFN-γ secretion by activated NK cells, 
enhancing antigen presentation and upregulation of antigen 
processing machinery (APM) in dendritic cells (DCs); (III) 
cross-priming of NK and DCs, activating tumor-associated 
(TA)-specific cytotoxic lymphocytes (CTLs) (28).
It is important that we continue to understand the factors 
affecting the response to Ab-coated tumor cells in their 
environment in order to create the next generation of mAbs 
and new therapeutic strategies to stimulate immune effector 
cells involved in ADCC.
NK-mediated ADCC as potential predictors of a 
successful clinical outcome
A few studies suggested a potential role of ADCC as 
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Figure 1 The antibody-dependent cell-mediated cytotoxicity 
complex. 
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prognosticators (collected in Table 1). For instance, 
considering cetuximab, available experimental and clinical 
data agree that there is a direct correlation between 
the receptor density on the target cell membrane and 
the intensity of the ADCC response. Similarly, in both 
oropharyngeal cancer and colorectal cancer (CRC), it has 
been reported that a large-scale intratumoral infiltration of 
NK cells is associated with improved prognosis. 
It is still unclear whether ADCC induced by cetuximab 
is associated with mutations in of RAS and BRAF genes 
in metastatic CRC (mCRC) (30,38). ADCC activities 
were shown to be significantly linked to the membrane 
expression of EGFR but not to the KRAS nor BRAF 
mutations. Conversely, Kasper et al. [2013] (39) suggest 
that RAS mutation defends at the same time against anti-
EGFR antibody-dependent cellular cytotoxicity and EGFR 
signalling blockade.
Immunotargeting of NK cells, γδ T cells, macrophages 
and DCs can enhance the anticancer properties of mAbs 
and elicit an effective immune response (40). NKT cells are 
a subpopulation of T lymphocytes that co-express αβ T-cell 
receptor (TCR) and markers that are usually associated 
with NKs. They have a wide range of immune effector 
properties. In particular, a subset of CD1d-dependent NKT 
cells exist which expresses an invariant TCR α chain (iNKT) 
cells. They rapidly respond to stress and inflammatory 
signals (41).
A number of independent studies have shown that a 
reduction of number of iNKT cells in the blood of patients 
with a variety of cancers. Interestingly, an increased 
frequency of peripheral blood iNKT cells heralds a more 
favourable response to therapy (42). Molling et al. (43) 
correlated a severe circulating iNKTs deficiency with 
poor clinical outcome in head and neck squamous cell 
carcinoma. Lo Nigro et al. (30,44) assessed the extent to 
which cetuximab-mediated ADCC and circulating iNKT 
cell levels have valid prognostic and predictive properties 
in mCRC treated with cetuximab in II and III lines, and 
examined how they correlate with EGFR level, KRAS/
NRAS/BRAF mutational status, progression-free survival 
(PFS) and overall survival (OS) in a prospective cohort 
of mCRC patients undergoing treatment with therapy 
based on cetuximab. They noticed that, at basal level, the 
combination of iNKT number and ADCC be identified a 
group of patients which had both characteristics above the 
respective median level together with a longer OS. This 
advantage appeared to be greater than the role played by 
ADCC by itself, giving weight to the theory that there is 
a positive interchange between iNKT and ADCC effector 
cells. No correlation between key SNPs was seen to be 
implicated in ADCC ability and OS nor was PFS found to 
be significant.
With the same approach, Lattanzio et al. [2017] (29) 
more recently delineated baseline ADCC in 28 cetuximab- 
and radiotherapy (RT)-treated HNSCC patients and in 
15 chemoradiation-treated patients and associated the 
values found with complete response and OS. They also 
considered the role of EGFR expression and studied the 
combined effect of EGFR and ADCC. High (above median 
value) baseline ADCC significantly correlated with outcome 
with respect to low (below median value), though not in 
non-cetuximab-treated patients. It was interesting to note 
that those patients with both high baseline ADCC and 
EGFR3+ levels obtained the best outcome with respect to 
the others.
At present, we do not know the mechanistic link 
sustaining the positive value of iNKT described above, and 
dedicated translational studies are needed in this direction.
Strategies potentially enhancing ADCC 
We will evaluate and describe some of the main potential 
approaches to enhance the antitumor activity of ADCC [for 
a complete review, refer to (25)]. 
Such strategies may involve attempts to augment the 
receptor affinity and activation of NK, accessibility to 
tumor site, combination with other molecules and immune-
modulatory strategies, i.e., RT and checkpoint blockage.
Receptor affinity
An effective approach to increasing ADCC might be to alter 
the Fc fragment so as to enhance NK-mediated ADCC. 
For instance, engineering mAbs to remove fucose sugar 
units from the Fc region increases binding with FcγR and 
therefore ADCC. Mogamulizumab (an anti-CCR4 mAb) is 
an afucosylated mAb which brought about ADCC against 
CCR4-positive cell lines successfully and hindered the 
growth of EBV-positive NK cell lymphomas in preclinical 
models (45,46). 
CD137 is an activating receptor on the NK cell 
membrane (8,47). The anti-CD137 (4-1BB) antibody activated 
NKs in a mouse model of B-cell lymphoma (48,49). The co-
activation with 4-1BB agonist antibody between rituximab 
cycles in vivo resulted in the NK-mediated complete 
regression of the subcutaneous murine lymphoma (1,48). 
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Table 1 Prognostic role of ADCC in the published literature
Prognostic role Study population
Method of ADCC  
determination
Type of publication Reference
High (above median value) 
baseline ADCC significantly 
correlated with outcome 
in patients treated with 
cetuximab. High basal of 
both ADCC and EGFR levels 
correlated with the best 
outcome
28 HNSCC patients treated with 
cetuximab and radiotherapy 
and in 15 patients treated with 
chemoradiation
Ex vivo non-radioactive 
LDH determination on 
purified NK cells
Experimental-translational (29)
High level of ADCC (above 
median value) correlates  
with OS
41 mCRC patients treated with 
cetuximab in II and III lines
Ex vivo non-radioactive 
LDH determination on 
purified NK cells
Experimental-translational (30)
Trend toward increased ADCC 
activity in patients with clinical 
benefit (either stable disease 
or response) compared 
with patients who did not 
experience clinical benefit
19 colorectal cancer, 3 HNSCC 
enrolled in a trial evaluated the 
combination of cetuximab with 
lenalidomide
5lCr release Experimental-translational (31)
Defects in ADCC is responsible 
of resistance to HER2-targeted 
drugs
Breast cancer Various Review (32)
Intratumoral T CD8+ and CD45+ 
lymphocytes infiltrate has a 
better prognostic value than 
the classic TMN classification 
factor
Colorectal cancer Various Review (33)
Cytotoxicity of expanded NK 
cells against HER2-positive 
gastric cancer cells could be 
increased by Herceptin and 
further augmented by lapatinib
Gastric cancer Calcein-release assay Experimental-translational (34)
ADCC was lower in breast 
cancer patients as compared 
to healthy controls. Prognostic 
value not investigated.
HER2/neu positive breast 
cancer patients receiving 
trastuzumab therapy either in 
an adjuvant (n=13) or metastatic 
(n=15) setting as well as from 
trastuzumab-naïve HER2/neu 
negative patients (n=15)
Three-color flow 
cytometric method
Experimental-translational (35)
Response to cetuximab  
positively correlated with 
tumor NK infiltration
5 mCRC patients MTT colorimetric assay Experimental-translational (36)
Lack of prognostic value 60 various cancer patients and 
24 with advanced disease
5lCr release Experimental-translational (37)
ADCC, antibody-dependent cellular cytotoxicity; OS, overall survival; LDH, lactate dehydrogenase; NK, natural killer; mCRC, metastatic 
colorectal cancer; IHC, immunohistochemistry; HER2/neu, epidermal growth factor receptor 2; HNSCC, head and neck squamous cell 
carcinoma; MTT, 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
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A new type II glycoengineered anti-CD20 mAb with 
increased FcγR III binding and ADCC is represented 
by obinutuzumab (GA101). Unlike rituximab, GA101 
induces NK cell activation regardless of the cells’ 
inhibitory immunoglobulin-like receptor (KIR) expression. 
Furthermore, its activity is not adversely modulated by 
KIR/HLA (25,46).
Several other promising combination strategies aimed 
at boosting NK cell ADCC responses to tumors are now 
being developed pre-clinically and clinically [for a complete 
list, refer to (50)]. 
mAb + radiation therapy 
An anti-tumor effect is obtained by radiation (RT) due to 
DNA damage being caused but the same RT may increase 
tumor susceptibility to immune response too. As a result, 
the immune response might modulate the effect of RT, and 
RT may increase immunotherapy efficacy (51) perhaps by 
causing inflammatory cytokines to be produced and tumor-
specific antigens to be released, as well as causing changes 
in the expression of immune susceptibility markers and in 
the on vasculature, which enhance immune control (52).
Moreover, RT upregulates the expression of tumor-
specific antigens, MHC class I, NKG2D ligand and the Fas 
death receptor; all these mechanisms have been shown to 
potentiate ADCC in experimental models (20).
mAb + matrix metalloproteases (MMPs) inhibitor 
It has been demonstrated that NK cells, once activated, 
discard FcγR IIIa from the cell membrane by activating 
MMPs (20,53,54). NK cell in vitro treatment with the MMP 
inhibitor, GM6001, redeems FcγR IIIa loss provoked by 
K562 tumor cells, but does not impede NKs degranulation, 
which points to the fact that FcγR IIIA shedding and 
NK cell degranulation are independent. It is, therefore, 
reasonable to suppose that by maintaining FcγR IIIa on 
the NK cell surface through an MMP inhibitor, the NK-
dependent ADCC might be enhanced without interfering 
with degranulation (55). Recently, Romee et al. [2013] 
determined one specific MMP, ADAM17, as the key MMP 
mediating the FcγR IIIa loss after NKs activation (19).
Combination of immune checkpoint inhibitors and NK  
cell therapy
PD-1 and ligands (PD-L1 and PD-L2) represent another 
important signalling pathway able to regulate NK cell 
and, as consequence, ADCC. It is now believed that PD-1 
and PD-L1 blockade firstly impact T-cell subsets, but, 
after activation, NK cells express PD-1 and send negative 
regulatory signals, which limit cytotoxicity (49,56).
In the study by Guo et al. [2016] (57), the introduction of the 
anti-PD1 antibody to NK cell therapy improves cells’ in vitro 
activity (i.e., higher levels of the NK activation receptors 
NKG2D, NKp44 and NKp30). They also incremented 
NK-mediated ADCC and drug efficacy in a in vivo model of 
multiple myeloma (MM) and in primary MMs (1,50). 
In particular, it was seen that PD-1 was upregulated on 
NK cells in patients with MMs expressing PD-L1, and the 
NK cell–mediated cytotoxicity of these tumors was shown 
to be potentiated by a PD-1 blocking antibody (58). 
In patients with MM, renal cell carcinoma and follicular 
lymphoma cytolytic activity of NK cells was restored by 
autologous NK cells with blocking anti-PD-1 antibodies 
(pidilizumab), alone or combined with rituximab (59,60). 
Anti-NKG2A antibodies 
CD94/NKG2A is an HLA-E-binding inhibitory receptor. 
It was seen that, in several solid tumors and hematological 
malignancies,  HLA-E might inhibit the cytotoxic 
properties of NKs and CD8+ cytotoxic T lymphocytes (61). 
Monalizumab (IPH2201), anti-NKG2A checkpoint inhibitor, 
has been evaluated in clinical trials in ovarian cancers, 
head and neck cancers, advanced malignancies and chronic 
lymphocytic leukemia (CLL) (62). Its use might represent 
a novel approach in NK-based immunotherapy not only 
enhancing the cytotoxic potential of the cells, but also 
hypothesizing a role tor them in ADCC augmentation (50).
Killer cell immunoglobulin-like receptors (KIRs)
The KIR family are key modulators of NKs activation. KIR 
molecules bind to the self MHC class I ligands (HLA-A, 
HLA-B, HLA-C) and transmit inhibitory signals that 
abrogate the effects of activating receptors. The application 
of blocking antibodies toward KIRs is the basis of an 
alternative checkpoint inhibitory strategy. Since MHC class 
I is virtually represented on all healthy cells, KIR molecules 
are regarded as being one of the principal mechanisms 
responsible for NK cell tolerance to self. In mice models 
of leukemia, it has been shown that the reduction of KIR-
mediated inhibitory signals in NK cells through antibody 
blockade increases NK cytotoxicity and possibly NK cell-
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mediated ADCC. A KIR-blocking mAb (IPH2102/BMS-
986015), lirilumab, has been tested in clinical research (8,27). 
Human NK cell function in vitro, in humanized mice, 
and, most recently, in clinical experimental patient sets, 
was shown to be boosted by another anti-KIR antibody 
(IPH2101) that blocks MHC-I recognition (1).
Glucocorticoid-induced TNF receptor family related  
gene (GITR)
Following cellular activation, the GITR is upregulated (27,63). 
GITR ligand (GITRL) is often represented on leukemia 
cells in AML and CLL, and weakens the activity of 
expressing GITR-NK cells (64). GITRL additionally 
inhibits the ADCC of NK cells induced by rituximab (65). 
In NK cells, the anti-GITR mAb TRX518 prevents GITR 
interaction, with its ligand GITRL, thus augmenting NK-
cell cytotoxicity and intensifying NK cell-mediated ADCC. 
A phase I study with TRX518 (NCT01239134) was carried 
out in melanoma (27).
CD27
CD27 (TNFRSF7), a costimulatory receptor on T cells, B 
cells and NKs, supplies a target for intensifying anticancer 
immunity (27,66). CD27 and interaction with its ligand, 
CD70, accelerated NK-mediated tumor clearance whilst 
causing an adaptive immune response. Anti-CD27 
antagonist therapy strongly induced ADCC in clinical trials 
of patients with solid tumors and hematologic cancers. In 
clinical trials, in solid and hematologic cancers, anti-CD27 
treatment increased ADCC dramatically (67).
Bruton’s tyrosine kinase (BTK) inhibitor
Ibrutinib, an irreversible BTK inhibitor, displays encouraging 
activity in CD20+ B-cell tumors and recently gained US FDA 
approval in mantle cell lymphoma (68). Ibrutinib inhibited 
NK cell cytokine secretion and cytotoxicity induced by 
both rituximab and trastuzumab. Yonezawa et al. [2016] (27) 
showed that the annulment of this antitumor efficacy is the 
result of the inhibition by ibrutinib of FcR-stimulated NK 
cell function, in particular ADCC. 
Adoptive transfer of ex vivo-activated NK cells 
Processes of ex vivo cytokine activation and expansion of 
NK cells have characterised recent approaches. Several 
cytokines [interleukin-2 (IL-2), IL-12, IL-15, IL-18, IL-21 
and type I IFNs] have been investigated to activate and 
expand NK cells ex vivo. IL-2 (46) is the most widely-
studied cytokine, as the co-administration of mAb and IL-2 
improves the NK cells’ antitumor activity (8,69,70).
ADCC activity against mAb-coated tumor cells has been 
increased by IL-2-activated lymphokine-activated killer 
(LAK) cells (71).
Recent efforts have concentrated on bettering methods for 
ex vivo NK cells expansion from peripheral blood mononuclear 
cells (PBMCs) in order to produce significant amounts of 
purified and functionally active NKs for clinical practice.
Following early reports of successful adoptive NK-
cell transfer, there has been considerable pre-clinical 
investigation carried out by many groups into the ideal 
manufacturing procedures for NK cell ex vivo manipulation. 
Various methods were optimized in the preclinical context 
and have been successfully transferred to the clinic (72-78).
In the process of NK expansion, effectors are activated 
to kill tumors more effectively, so that it is possible to 
infuse them into patients. It may be that autologous NK 
cells are partially tolerant to self-tumors and, in some 
contexts, have a lower anti-cancer activity with respect to 
the allogeneic ones (20). 
It has been demonstrated in various investigations that 
the infusion of enriched haploidentical NK cells, particularly 
those taking advantage of KIR/HLA mismatches, is safe and 
effective in children, adults and elderly cancer patients (75-77). 
Despite the fact that this is an encouraging approach, 
the need for specialized procedures and equipment and 
good manufacturing practices, together with the various 
logistical issues, has concentrated these adoptive NK cell 
therapies into few specialized centres (78). Notwithstanding 
this, it has been shown that the centralized manipulation, 
conservation and safe shipping of active NKs for infusion to 
distant hospitals is possible and the improved practice might 
become more common (79). 
Genetically-engineered killer engagers
Based upon genetically-engineered bispecific killer engagers 
(BiKEs) and trispecific killer engagers (TriKEs), alternative 
approaches have emerged to augment the activity and 
killing specificity of NK cells [for a complete review, refer 
to (50)]. Conjugate formation between tumor and NK cells 
is promoted by those antibodies. They normally bind both 
the FcγR IIIa/CD16 and tumor antigen (80). A bispecific 
tetravalent antibody targeting both CD16 and CD30 was 
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recently introduced in relapsed Hodgkin lymphoma (81). 
Greater cytotoxicity was displayed by those constructs with 
respect to conventional antibodies that are independent of 
the FcγR IIIa (82).
Furthermore, a tetraspecific killer engager (TetraKE) 
based on a bispecific NK cell engager (BiKE) platform, 
consisting of single-chain variable fragments binding FcγR 
III on NK cells, EpCAM on carcinoma cells and CD133 on 
cancer stem cells, was created so as to increase ADCC (83). 
BiKEs were constructed to create an immune bridge 
between cancer and NK cells. Additionally, NK cell-related 
proliferation was enhanced by an IL-15-crosslinker. IL-
15 regulates NK cells, which can augment ADCC, LAK 
activity and IFN, TNF and GM-CSF signalling (84-86). 
All of these functions activated by IL-15 play a part in 
improving cancer defence.
Conclusions
mAbs evolved from original mouse antibodies, chimeric 
antibodies, humanized and fully human antibodies. 
However, their evolution to a more efficient weapon is still 
in progress. The present challenge is to engineer them to 
improve anti-tumor efficacy. Other methods of improving 
anti-tumor effects exist in addition to optimising the mAb 
itself, one of which is to improve ADCC by coupling mAbs 
with immune stimulatory agents. 
Though ADCC is to date overshadowed by the exciting 
results of target immunotherapy, such as immune check-point 
inhibitors, due to the recent progress in the NK cell biology 
and translational research, it is hoped that the therapy with 
NK cells become first line in the immunotherapy of cancer in 
the coming years.
The majority of current data, presented in this work, 
refer to circulating NK. An open issue and current 
challenge would be to explore the presence and role of NK 
at the tumor tissue level, comparing with findings in the 
peripheral blood.
A direct tumor infiltration by NK cells has been reported 
in several tumor settings but its biological role and clinical 
significance is still not completely clear and is sometimes 
controversial (87-89). For instance, similarities between 
intratumoral NK and tolerogenic NK present in the 
maternal decidua have been described (89).
Recently, it was reported that intratumoral NK may 
cluster together with stimulatory DCs sustaining their 
positive role, through the production of FLT3L, toward an 
effective T cell-mediated antitumor activity and response to 
checkpoint inhibitors (90).
The integration in the clinical studies with next 
generation IHC methodologies and multiplex analyses will 
be crucial to advance our knowledge of these topics. 
Most probably, the beneficial effects in cancer therapy 
might be applied by a combination of ex vivo stimulated 
NK cells and other immune drugs (i.e., mAbs and immune 
checkpoint inhibitors) and/or standard therapies (i.e., radio- 
and chemo-therapy). 
ADCC might be improved by drugs able to enhance NK 
cell activity, as they are regarded as having a significant role 
in mAb-mediated ADCC against tumor cells. 
In particular, KIRs and FcR genotypes may be useful in 
forecasting the clinical outcome of ADCC-inducing mAbs, 
thus enabling a more personalized therapy. 
Following continuing preclinical research into the 
potential synergy of combinations of drugs, and the 
mechanisms at their base, the rational design of early-
phase clinical trials and the use of robust biomarkers 
(e.g., increase, activation or cytolytic function of NK cell 
populations) will be enabled. Any combinations displaying 
the proof-of-principle will be moved on to later-phase trials 
and will perhaps confirm if a true synergy exists.
Without doubt some mAbs/immunomodulatory drugs 
combinations, as reviewed in this paper, will become an 
important tool in anticancer therapies over the next few years.
The main challenge remaining is the difficulty to 
distinguish in the clinical setting, between the target effect 
that many mAbs exert against specific cell membrane 
receptors and the ADCC effect that they also can induce.
Therefore, despite the fact that the evidence existing 
in animal models and the many small studies in humans 
continue to provide convincing weight, the real strength of 
ADCC in clinical practice remains unclear.
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